IL6R and prostate carcinoma: Currently, therapeutic blockade of IL-6/JAK/STAT3 signaling using IL-6 ligand-binding antibodies, IL-6R blocking antibodies, or specific compounds that inhibit the activity of JAK and STAT3 have been tested pre-clinically for prostate cancer, non-small cell lung cancer, ovarian cancer, breast cancer and colon cancer.